AGIO · Company research
Agios Pharmaceuticals, Inc. (AGIO): Stock News & Events
Recent company-linked news records available in the database.
RESEARCH CONTEXT
Understand the numbers
Recent company-linked news records available in the database. Use period, currency, units and source fields when interpreting values.
26records availableHealthcare
Stock News & Events data
Database-backed records only
| title | summary | url | source | published at | sentiment | sentiment score | relevance score |
|---|---|---|---|---|---|---|---|
| Danaher Gears Up to Post Q3 Earnings: What Lies Ahead for the Stock? | Danaher Corporation is expected to report Q3 2026 revenues of $26.3 billion, up 8.2% year-over-year, driven by strength in Biotechnology, Diagnostics, and Life Sciences segments, plus the Masimo acquisition. However, rising input costs, product mix changes, and currency headwinds may pressure profits. The company has a positive Earnings ESP of +0.30% and Zacks Rank of 2 (Buy). | View source ↗ | Zacks Investment Research | Oct 16, 2026 | bullish | 1 | 1 |
| Danaher Gears Up to Post Q3 Earnings: What Lies Ahead for the Stock? | Danaher Corporation is expected to report Q3 2026 revenues of $26.3 billion, up 8.2% year-over-year, driven by strength in Biotechnology, Diagnostics, and Life Sciences segments, plus the Masimo acquisition. However, rising input costs, product mix changes, and currency headwinds may pressure profits. The company has a positive Earnings ESP of +0.30% and Zacks Rank of 2 (Buy). | View source ↗ | Zacks Investment Research | Oct 16, 2026 | bullish | 1 | 1 |
| 4 High-Risk Stocks Built for Big Returns | The article highlights four high-risk, high-reward stocks: Agios Pharmaceuticals awaiting FDA approval for mitapivat to treat sickle cell disease; Navitas Semiconductor pivoting toward AI data centers and high-power chips; Joby Aviation developing eVTOL transportation services with autonomous capabilities; and Viking Therapeutics developing obesity drug VK2735 with potential in a multi-billion dollar market. All require patience but offer significant upside if their respective catalysts materialize. | View source ↗ | The Motley Fool | Oct 14, 2026 | bullish | 0.571 | 1 |
| 4 High-Risk Stocks Built for Big Returns | The article highlights four high-risk, high-reward stocks: Agios Pharmaceuticals awaiting FDA approval for mitapivat to treat sickle cell disease; Navitas Semiconductor pivoting toward AI data centers and high-power chips; Joby Aviation developing eVTOL transportation services with autonomous capabilities; and Viking Therapeutics developing obesity drug VK2735 with potential in a multi-billion dollar market. All require patience but offer significant upside if their respective catalysts materialize. | View source ↗ | The Motley Fool | Oct 14, 2026 | bullish | 0.571 | 1 |
| Agios Pharmaceuticals, Inc. (AGIO) stock price, news, quote and history - Yahoo Finance UK | Agios Pharmaceuticals, Inc. (AGIO) stock price, news, quote and history Yahoo Finance UK | View source ↗ | Yahoo Finance UK | Oct 11, 2026 | neutral | 0 | 0.6 |
| (AGIO) and the Role of Price-Sensitive Allocations - Stock Traders Daily | (AGIO) and the Role of Price-Sensitive Allocations Stock Traders Daily | View source ↗ | Stock Traders Daily | Oct 10, 2026 | neutral | 0 | 0.6 |
| Agios Pharmaceuticals (AGIO) Could Be 28% Undervalued Following Its November Results Call Date - Yahoo Finance | Agios Pharmaceuticals (AGIO) Could Be 28% Undervalued Following Its November Results Call Date Yahoo Finance | View source ↗ | Yahoo Finance | Oct 10, 2026 | neutral | 0 | 0.6 |
| AGIO Stock Hits Over 7-Month Highs – FDA Catalyst, ‘Seasonally Strong’ Q2 Earnings Estimate Drive Optimism - Stocktwits | AGIO Stock Hits Over 7-Month Highs – FDA Catalyst, ‘Seasonally Strong’ Q2 Earnings Estimate Drive Optimism Stocktwits | View source ↗ | Stocktwits | Oct 7, 2026 | neutral | 0 | 0.6 |
| AGIO Stock Sinks 29% in Three Months: Here's What You Need to Know | Agios Pharmaceuticals' stock declined 29% over three months following the discontinuation of tebapivat across all indications after failing to demonstrate differentiation from existing treatments. With tebapivat no longer advancing, the company is increasingly dependent on mitapivat, which showed strong 259.3% year-over-year sales growth to $44.7 million in Q2 2026. However, intensifying competition from Novo Nordisk's etavopivat in the sickle cell disease market poses challenges as Agios awaits FDA approval for mitapivat in SCD by November 2026. | View source ↗ | Zacks Investment Research | Oct 6, 2026 | neutral | 0 | 1 |
| AGIO Stock Sinks 29% in Three Months: Here's What You Need to Know | Agios Pharmaceuticals' stock declined 29% over three months following the discontinuation of tebapivat across all indications after failing to demonstrate differentiation from existing treatments. With tebapivat no longer advancing, the company is increasingly dependent on mitapivat, which showed strong 259.3% year-over-year sales growth to $44.7 million in Q2 2026. However, intensifying competition from Novo Nordisk's etavopivat in the sickle cell disease market poses challenges as Agios awaits FDA approval for mitapivat in SCD by November 2026. | View source ↗ | Zacks Investment Research | Oct 6, 2026 | neutral | 0 | 1 |
| AGIO Stock Sinks 29% in Three Months: Here's What You Need to Know - TradingView | AGIO Stock Sinks 29% in Three Months: Here's What You Need to Know TradingView | View source ↗ | TradingView | Oct 6, 2026 | neutral | 0 | 0.6 |
| AGIO Feb 2027 55.000 call (AGIO270219C00055000) Stock Price, News, Quote & History - Yahoo! Finance Canada | AGIO Feb 2027 55.000 call (AGIO270219C00055000) Stock Price, News, Quote & History Yahoo! Finance Canada | View source ↗ | Yahoo! Finance Canada | Oct 5, 2026 | neutral | 0 | 0.6 |
| Agios Pharmaceuticals (AGIO) Slides 2.09% to $31.80 as Shares Drift Toward Key Support - Option Strike Build - siam.in | Agios Pharmaceuticals (AGIO) Slides 2.09% to $31.80 as Shares Drift Toward Key Support - Option Strike Build siam.in | View source ↗ | siam.in | Oct 3, 2026 | neutral | 0 | 0.6 |
| Agios' Growth Story Hinges on Mitapivat's Commercial Expansion | Agios Pharmaceuticals' mitapivat-based drugs (Pyrukynd and Aqvesme) generated $44.7 million in Q2 2026 revenue, up 259% year-over-year, driven by early thalassemia adoption. However, the discontinuation of pipeline drug tebapivat and intensifying competition from Novo Nordisk's etavopivat in sickle cell disease have made the company heavily dependent on mitapivat's commercial success. | View source ↗ | Zacks Investment Research | Oct 2, 2026 | bullish | 0.8 | 1 |
| Agios' Growth Story Hinges on Mitapivat's Commercial Expansion | Agios Pharmaceuticals' mitapivat-based drugs (Pyrukynd and Aqvesme) generated $44.7 million in Q2 2026 revenue, up 259% year-over-year, driven by early thalassemia adoption. However, the discontinuation of pipeline drug tebapivat and intensifying competition from Novo Nordisk's etavopivat in sickle cell disease have made the company heavily dependent on mitapivat's commercial success. | View source ↗ | Zacks Investment Research | Oct 2, 2026 | bullish | 0.8 | 1 |
| Agios Pharmaceuticals Stock (AGIO) Opinions on Trading Strategies - Quiver Quantitative | Agios Pharmaceuticals Stock (AGIO) Opinions on Trading Strategies Quiver Quantitative | View source ↗ | Quiver Quantitative | Sep 18, 2026 | neutral | 0 | 0.6 |
| Agios Pharmaceuticals (AGIO) Stock Sinks As Cash Burn Clouds Mitapivat Ramp - Simply Wall Street | Agios Pharmaceuticals (AGIO) Stock Sinks As Cash Burn Clouds Mitapivat Ramp Simply Wall Street | View source ↗ | Simply Wall Street | Jul 31, 2026 | neutral | 0 | 0.6 |
| Why Is AGIO Stock Falling Today? - Yahoo Finance | Why Is AGIO Stock Falling Today? Yahoo Finance | View source ↗ | Yahoo Finance | Jul 21, 2026 | neutral | 0 | 0.6 |
| Strength Seen in Agios Pharmaceuticals (AGIO): Can Its 17.7% Jump Turn into More Strength? - Yahoo Finance | Strength Seen in Agios Pharmaceuticals (AGIO): Can Its 17.7% Jump Turn into More Strength? Yahoo Finance | View source ↗ | Yahoo Finance | Jul 8, 2026 | neutral | 0 | 0.6 |
| Here's Why Agios Pharmaceuticals Stock Soared Today (Hint: It's FDA-Related) - Yahoo Finance | Here's Why Agios Pharmaceuticals Stock Soared Today (Hint: It's FDA-Related) Yahoo Finance | View source ↗ | Yahoo Finance | Jul 7, 2026 | neutral | 0 | 0.6 |
| AGIO Stock Hits Over 7-Month Highs – FDA Catalyst, ‘Seasonally Strong’ Q2 Earnings Estimate Drive Optimism - Yahoo Finance | AGIO Stock Hits Over 7-Month Highs – FDA Catalyst, ‘Seasonally Strong’ Q2 Earnings Estimate Drive Optimism Yahoo Finance | View source ↗ | Yahoo Finance | Jul 7, 2026 | neutral | 0 | 0.6 |
| AGIO Stock Surges 35% in Six Months: What's Driving It? - TradingView | AGIO Stock Surges 35% in Six Months: What's Driving It? TradingView | View source ↗ | TradingView | Jun 18, 2026 | neutral | 0 | 0.6 |
| $AGIO stock is down 22% today. Here's what we see in our data. - Quiver Quantitative | $AGIO stock is down 22% today. Here's what we see in our data. Quiver Quantitative | View source ↗ | Quiver Quantitative | Apr 20, 2026 | neutral | 0 | 0.6 |
| Agios Pharmaceuticals stock tumbles 25% after Novo data - Investing.com | Agios Pharmaceuticals stock tumbles 25% after Novo data Investing.com | View source ↗ | Investing.com | Apr 20, 2026 | neutral | 0 | 0.6 |
| Why Did AGIO (Agios Pharmaceuticals) Stock Surge 14% Today? - Stocktwits | Why Did AGIO (Agios Pharmaceuticals) Stock Surge 14% Today? Stocktwits | View source ↗ | Stocktwits | Mar 5, 2026 | neutral | 0 | 0.6 |
| Agios Pharmaceuticals, Inc. (AGIO) Stock - Gotrade | Agios Pharmaceuticals, Inc. (AGIO) Stock Gotrade | View source ↗ | Gotrade | Feb 2, 2026 | neutral | 0 | 0.6 |
Informational research only, not financial advice. Forecasts are uncertain and can be wrong.